Abstract:Primary cutaneous lymphomas comprise a heterogeneous group of extranodal non-Hodgkin lymphomas (NHL) that arise from skin resident lymphoid cells and are manifested by specific lymphomatous cutaneous lesions with no evidence of extracutaneous disease at the time of diagnosis. They may originate from mature T-lymphocytes (70% of all cases), mature B-lymphocytes (25-30%) or, rarely, NK cells. Cutaneous T-cell lymphomas (CTCL) comprise a heterogeneous group of T-cell malignancies including Mycosis Fungoides (MF) the most frequent subtype, accounting for approximately half of CTCL, and Sézary syndrome (SS), which is an erythrodermic and leukemic subtype characterized by significant blood involvement. The mutational landscape of MF and SS by NGS include recurrent genomic alterations in the TCR signaling effectors (i.e., PLCG1), the NF-κB elements (i.e., CARD11), DNA damage/repair elements (TP53 or ATM), JAK/STAT pathway elements or epigenetic modifiers (DNMT3). Genomic copy number variations appeared to be more prevalent than somatic mutations. Other CTCL subtypes such as primary cutaneous anaplastic large cell lymphoma also harbor genetic alterations of the JAK/STAT pathway in up to 50% of cases. Recently, primary cutaneous aggressive epidermotropic T-cell lymphoma, a rare fatal subtype, was found to contain a specific profile of JAK2 rearrangements. Other aggressive cytotoxic CTCL (primary cutaneous γδ T-cell lymphomas) also show genetic alterations in the JAK/STAT pathway in a large proportion of patients. Thus, CTCL patients have a heterogeneous genetic/transcriptional and epigenetic background, and there is no uniform treatment for these patients. In this scenario, a pathway-based personalized management is required. Cutaneous B-cell lymphoma (CBCL) subtypes present a variable genetic profile. The genetic heterogeneity parallels the multiple types of specialized B-cells and their specific tissue distribution. Particularly, many recurrent hotspot and damaging mutations in primary cutaneous diffuse large B-cell lymphoma of the leg type, involving MYD88 gene, or BCL6 and MYC translocations and BLIMP1 or CDKN2A deletions are useful for diagnostic and prognostic purposes for this aggressive subtype from other indolent CBCL forms.

Giant Primary Cutaneous Follicle Centre B-Cell Lymphoma

Primary cutaneous DLBCL non-GCB type: challenges of a rare case

Clinical and Histological Features of Primary Testicular Diffuse Large B-cell Lymphoma: a Single Center Experience in China

Primary cutaneous large B-cell lymphoma of the leg: Histogenetic analysis of a controversial clinicopathologic entity

Protection of bovine seryl-transfer ribonucleic acid (seryl-tRNA) synthetase from chemical modification by its substrates, and some kinetic parameters.

Update in Diagnosis and Management of Primary Cutaneous B-Cell Lymphomas

Clinician's perspective on the diagnosis of primary cutaneous B-cell lymphoma

Primary cutaneous follicle center lymphoma in a 16‐year‐old girl

Bullous pemphigoid with primary cutaneous diffuse large B-cell lymphoma

Primary Cutaneous Diffuse Large B-cell Lymphoma,leg Type:A Clinicopathological Analysis of 17 Cases

A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL)

Paediatric cutaneous lymphomas including rare subtypes: A 40‐year experience at a tertiary referral centre

Genetics Abnormalities with Clinical Impact in Primary Cutaneous Lymphomas

Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance

B-cell lymphoma of the skin. Clinical observation

Fractures of the femoral neck in children: long-term follow-up in 62 hip fractures.

Follicular Lymphoma Presenting With Symptomatic Bone Involvement: A Clinicopathologic and Molecular Analysis of 16 Cases

Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type: a Study of Clinicopathology,immunophenotype and Gene Rearrangement

Intravascular Large B-cell Lymphoma with Cutaneous Manifestations: a Clinicopathologic, Immunophenotypic and Molecular Study of Three Cases

Clinical features, treatment options and outcomes in primary cutaneous B‐cell lymphomas: a real‐world, multicenter, retrospective study

[Synthesis of 3-substituted indolones-(2)].